INVO Bioscience, a Florida company, has just won European regulatory approval for its INVOcell culture and retention device. The product is part of the INVO Solution, which involves introducing sperm to an egg within the INVOcell device and then placing the device within the vaginal cavity of the woman seeking to become pregnant.
After three days of incubation within the woman, the device is removed and the resulting embryos can be analyzed in a lab. The optimal candidates are chosen and then transferred into the uterus. The overall procedure provides a more natural incubation process, with conception happening in vivo.
The INVO Bioscience is already FDA approved and available in the United States.